28.06.2010 • News • Arkema • BASF • joint venture

Solvin and Arkema Buy Back Holdings in Vinyls Production JV

Arkema and SolVin (a joint venture between Solvay and BASF) have decided to each buy back the minority cross-holdings in the vinyls joint venntures, effective July 1. This affects the companies'  joint production entities for VCM (Vinylfos and Vinilis) and PVC (Vinylberre and Vinilis). Arkema will be the sole shareholder of Vinylfos and Vinylberre. Following this deal, both partners will regain their respective independence on the production sites in which they held a majority stake.

The companies said the decision was made in order to streamline the three manufacturing structures. It was also announced that the agreement will have no impact either on the workforce concerned or on Arkema's results.

(6/28/2010)

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Top-Feature

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.